Epigenetic Biomarker Detection for Cervical Cancer Screening

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting and characterizing cervical cancer face limitations due to low sensitivity and poor reproducibility, particularly in resource-limited settings, and there is a need for more effective biomarkers for early detection and monitoring.

Innovation Solution

The development of a method and kit for identifying epigenetic silencing of specific genes (GGTLA4, FKBP6, ZNF516, SAP130, and INTS1) in uterine cervical cells or nucleic acids, using reagents that modify methylated cytosine residues and oligonucleotide primers that specifically hybridize to these genes' regions, to assess the presence and amount of epigenetic silencing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cytological screening and HPV infection tests are used for cervical cancer detection, then the screening coverage is broad, but the sensitivity and reproducibility are low

Engineering Contradiction:

Improvedetection sensitivityVSAvoidtest method complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the detection parameter from general cytological features to specific epigenetic biomarkers (DNA methylation patterns, histone modifications, non-coding RNA expression). This parameter change enables more sensitive and specific detection of cervical cancer while maintaining a manageable test complexity through focused measurement of key molecular signatures.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the mechanical/cytological examination system with a molecular biology-based detection system. Instead of visual inspection of cellular morphology, the invention uses molecular assays to detect epigenetic alterations, thereby improving sensitivity and reproducibility through objective molecular measurements.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Measurement precision

If existing biomarker methods are used for cervical cancer detection, then the testing procedure is simple, but the early detection capability is limited

Engineering Contradiction:

Improveearly detection accuracyVSAvoidbiomarker detection difficulty

Core Design Contradiction:

Measurement precisionVSDifficulty of detecting and measuring

Solution Approach 1:

The patent detects epigenetic alterations that occur early in carcinogenesis, before invasive cancer develops. By measuring DNA methylation patterns, histone modifications, and non-coding RNA expression in precursor lesions, the invention enables early detection with high accuracy, allowing intervention before the disease progresses to advanced stages.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses epigenetic markers as intermediary indicators of cancer risk and progression. These molecular signatures serve as mediators that reflect underlying biological processes and predict clinical outcomes, enabling accurate early detection without requiring direct observation of malignant cells.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If resource-limited settings are considered for cervical cancer screening, then the accessibility is improved, but the detection effectiveness decreases

Engineering Contradiction:

Improvescreening accessibilityVSAvoiddetection effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent develops epigenetic biomarker assays that can be applied universally across different resource settings. The molecular detection methods for DNA methylation, histone modifications, and non-coding RNAs can be adapted to various platforms, from simple point-of-care tests to more sophisticated laboratory-based assays, maintaining detection effectiveness while improving accessibility in resource-limited environments.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a sensitive and specific method for diagnosing and characterizing cervical cancer, potentially improving early detection and monitoring, with higher sensitivity and specificity compared to existing methods, and can be used in combination with HPV testing.

Implementation Method 1

reagents that modify methylated cytosine residues but not non-methylated cytosine residues

Methodology Applied

Scientific EffectMethylation:

Implementation Method 2

oligonucleotide primers that specifically hybridize under amplification conditions to a region of a gene

Methodology Applied

Scientific EffectHybridization:

Data Source

PatentUS8859468B2Hypermethylation biomarkers for detection of cervical cancer

Publication Date: 2014.10.14 JOHNS HOPKINS UNIVERSITY

AI summary

Pap smears and HPV infection tests do not distinguish between lesions that will progress to an invasive carcinoma and those that will not. We aimed to identify epigenetic biomarkers for diagnosis and progression monitoring of premalignant lesions in cervical cancer. Hypermethylated genes were identified as potential biomarkers after validation by MSP, including GGTLA4 and ZNF516. The methylation frequency for these two genes was higher in tumor: GGTLA4 (100%) and ZNF516 (96%); than in normal samples: GGTLA4 (12%) and ZNF516 (16%). The methylation status of GGTLA4 showed a progression in methylation frequency from normal samples to invasive carcinoma. The immunohistochemical expression was lower in tumor for both: GGTLA4 (50.8%) and ZNF516 (66.2%); than in normal samples: GGTLA4 (71.2%) and ZNF516 (88.1%) (p<0.05). In conclusion, we identified methylation biomarkers for the molecular screening and characterization of cervical cancer.